anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a tin-like powder film agent and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The tin-like powder film agent comprises the following raw materials by weight: 70-90 parts of medicine superfine powder and 15-30 parts of an excipient. The medicine superfine powder is composed of the superfine powder of ivory crumbs, indigo naturalis, human nails, charcoal uroctea, pearl, borneol and calculus bovis factitious. The excipient comprises a film agent matrix, a corrigent, a coloring agent and a humectant, wherein the film agent matrix is one of polyvinyl alcohol, hydroxypropyl methylcellulose, gelatin, arabic gum, soluble starch and CMC-Na. The preparation method comprises five steps of preparing slurry of film-forming materials, preparing the materials, coating, drying and packaging. The film agent prepared by the invention can be directed at infected parts in an oral cavity, can be dissolved quickly, can be used quantitatively and has a definite therapeutic effect.
PROBLEM TO BE SOLVED: To make savable the time and labor much more than usual by issuing the totalization of included clinical data and the totalization of included diagnosis and treatment data which are included. SOLUTION: After issue condition settings of a totalization table are specified, a totalizing task processing part 22 starts a condition setting processing part 23 and then a condition setting screen is displayed on the screen of a display device 25. Those conditions are stored in an issue condition file 13. Then, the totalizing task processing part 22 actuates a document issuing process part 24, which reads conditions of totalization out of the issue condition file 13 and issues a totalization table meeting the conditions. Namely, the diagnosis and treatment data are read out of a diagnosis and treatment data base 12 and their insurance points are totalized by classifications according to the condition specification of inclusion parts or included parts.  Consequently, the totalization when diagnosis and treatment contents are included and the totalization when not can be easily obtained.
PROBLEM TO BE SOLVED: To obtain an enteric nutritional supplementary composition effective in treatment and prevention of inflammatory diseases of the gastrointestinal duct, e.g. Crohn's disease. SOLUTION: This composition comprises (a) casein rich in TGF-β2, (b) a lipid source which supplies approximately 35 to 50% of energy, and (c) a carbohydrate source. One of the preferred embodiments of the composition is as follows: the casein contains 1.2 to 2.0μg/g of TGF-β2, or 10 to 40μg of TGF-β2 is present in 100g of the composition. The lipid source is composed of a mixture of 20wt.% or less of medium-chain triglyceride and long-chain triglyceride, and contains polyunsaturated essential fatty acids which supply 10% or less of the lipid energy. The composition has an energy content in a range from 800 to 1200kcal/l, of which 10 to 14.5% is supplied by the casein.
BACKGROUND: White adipose tissue (WAT) has a key role in maintaining energy balance throughout the body, and their dysfunction take part in the regulation of diabetes mellitus. However, the internal regulatory mechanisms underlying are still unknown.
METHODS AND RESULTS: We generated adipocyte-specific FAK KO (FAK-AKO) mice and investigated their phenotype. The cascade of adipocyte, macrophage in adipocyte tissues, and pancreatic β-cells were proposed in FAK-AKO mice and validated by cell line studies using 3T3-L1, Raw264.7 and Min6. The FAK-AKO mice exhibited glucose intolerance, reduced adipose tissue mass and increased apoptosis, lipolysis and inflammatory response in adipose tissue. We further demonstrate that adipocyte FAK deletion increases β cell apoptosis and inflammatory infiltrates into islets, which is potentiated if mice were treated with STZ. In the STZ-induced diabetes model, FAK AKO mice exhibit less serum insulin content and pancreatic β cell area. Moreover, serum pro-inflammatory factors increased and insulin levels decreased after glucose stimulation in FAK AKO mice. In a parallel vitro experiment, knockdown or inhibition of FAK during differentiation also increased apoptosis, lipolysis and inflammatory in 3T3-L1 adipocytes, whereas the opposite was observed upon overexpression of FAK. Moreover, coculturing LPS-treated RAW264.7 macrophages with knockdown FAK of 3T3-L1 adipocytes increased macrophage pro-inflammatory response. Furthermore, conditioned medium from above stimulated Min6 cells apoptosis (with or without STZ), whereas the opposite was observed upon overexpression of FAK. Mechanistically, FAK protein interact with TRAF6 in adipocytes and knockdown or inhibition of FAK activated TRAF6/TAK1/NF-κB signaling, which exacerbates inflammation of adipocytes themselves.
CONCLUSION: Adipocyte FAK deletion promotes both adipocyte apoptosis and adipose tissue inflammation. Pro-inflammatory factors released by the FAK-null adipose tissue further trigger apoptosis in pancreatic islets induced by the administration of STZ, thereby exacerbating the diabetes mellitus. This study reveals a link between FAK-mediated adipose inflammation and diabetes mellitus, a mechanism that has not been previously recognized.
Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
OBJECTIVE: To analyze the influencing factors for patellofemoral joint (PFJ) overstuffing following total knee arthroplasty (TKA) without patella resurfacing, and explore the effect of PFJ overstuffing on clinical efficacy.
METHODS: A retrospective analysis was conducted on 168 patients with end-stage knee osteoarthritis who underwent TKA without patella resurfacing at our hospital between Match 2019 and September 2021. The clinical data of these patients were retrospectively analyzed. In this study, PFJ overstuffing was defined as a postoperative PFJ distance greater than 1 mm compared to the preoperative measurement. The occurrence of postoperative PFJ overstuffing was counted. The patients were divided into the overstuffing group (n = 109) and the non-overstuffing group (n = 59) to count the patellar thickness and thickness of femoral anterior condyle in all patients before and after surgery, and analyze the influencing factors for postoperative PFJ overstuffing in such patients. Patients were followed up for 2 years to compare the recovery time of postoperative pain, score of visual analogue scale (VAS) and flexion activity between the two groups.
RESULTS: There was no significant difference in patellar thickness between preoperative and postoperative measurements of the patients (P > 0.05). However, the thickness of the femoral anterior condyle and the PFJ distance after surgery increased significantly compared with those before surgery (P < 0.05). Among the 168 patients, 109 cases (64.88%) experienced PFJ overstuffing. The risk of PFJ overstuffing was higher in female patients than in male (P < 0.05). The preoperative thickness of the femoral anterior condyle in the overstuffing group was significantly smaller compared to the non-overstuffing group (P < 0.001). Compared with the non-overstuffing group, the overstuffing group had longer recovery time of postoperative pain (P < 0.05), and had lower flexion activity at 2 years after surgery (P < 0.001). However, no significant difference was found in VAS score between the overstuffing group and the non-overstuffing group at 2 years after surgery (P > 0.05). Spearman rank correlation analysis indicated females tend to have a lower preoperative thickness of the femoral anterior condyle (r=-0.424, P < 0.001), as well as a positive postoperative PFJ overstuffing (r = 0.237, P < 0.05). Furthermore, there was a negative correlation between preoperative thickness of the femoral anterior condyle and postoperative PFJ overstuffing (r=-0.540, P < 0.001).
CONCLUSION: Following TKA without patella resurfacing, there is a high risk of PFJ overstuffing, particularly among female patients and those with a small thickness of the femoral anterior condyle. Therefore, special attention should be given to these high-risk groups during clinical treatment.
PURPOSE:To obtain a plaster for poultice having excellent adhesion and shape retention as well as high safety, by using a reaction product of a protein having amino groups on side chains and a diacetal compound. CONSTITUTION:A gelling retardant such as calcium chloride, urea, etc., is added to an aqueous solution of a protein (e.g. gelatin, proteose, etc.) having amino groups on side chains. An aqueous solution of a diacetal compound expressed by the formula (R is 1-4C alkyl; A is oxyethylene or oxypropylene; m is 1-3,000) is added to the protein solution containing the gelling retardant to subject the protein having amino groups on the side chains to partial crosslinking. The resultant reaction product is used as the aimed plaster for poultice. The plaster is able to keep strong adhesive property also after evaporating water content in the plaster, by blending a hydrophilic tackifier (e.g. glycerin or ethylene glycol) into the plaster.
Systems and methods are provided for medical monitoring of a patient at a patient premises. A medical-data collection device is adapted to collect medical data from the patient. The medical-data collection device is interfaced with a transport medium internal to the patient premises. A network interface device is also provided with multiple application devices interfaced with the transport medium internal to the patient premises. One of the application devices is a medical-monitoring application device adapted to process the collected medical data. Another of the application devices is adapted to exchange data with a transport medium external to the patient premises. A processor in communication with the application devices is adapted to coordinate transmission of the collected medical data over the transport medium external to the patient premises.
Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
INTRODUCTION: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an infrequent hereditary disorder distinguished by fibrofatty replacement of the myocardium in the right ventricular, which predisposes individuals to life-threatening arrhythmias. This case delineates an ARVC patient who suffered recurrent bouts of sustained ventricular tachycardia (VT). In this case, we mainly discuss the application of myocardial contrast echocardiography (MCE) in displaying myocardial fibrosis in patients with ARVC.
CASE PRESENTATION: A 43-year-old male experienced three episodes of unexplained VT over an eight-year period, accompanied by symptoms of chest discomfort, palpitations and dizziness. Coronary angiography revealed no significant coronary stenosis. The electrocardiogram (ECG) results indicated characteristic epsilon waves in right precordial leads, and subsequent echocardiography identified right ventricular enlargement and right ventricular systolic dysfunction. MCE further disclosed regional myocardial ischemia at the epicardium of the left ventricular apex. Ultimately, cardiovascular magnetic resonance imaging (CMR) corroborated the ARVC diagnosis, highlighting linear intensification in the right ventricle during the delayed enhancement.
CONCLUSION: Prompt identification of ARVC is crucial for timely intervention and management. MCE may offer an effective and valuable technique for the detection of myocardial involvement in ARVC patient.
The present invention provides a pharmaceutical formulation for oral administration which is pharmaceutically acceptable, and which produces a desired therapeutic response, in tablet, caplet or other compressed form which comprises the potassium, sodium or Tris salt of oxaprozin, the tablet, caplet or other compressed form of the pharmaceutical formulation generally becoming about 75% dissolved in phosphate buffer media within about 30 minutes. The present invention also provides a pharmaceutical formulation for oral administration which is pharmaceutically acceptable, and which produces a therapeutic response, in tablet, caplet or other compressed form which comprises: (a) the potassium, sodium or Tris salt of oxaprozin as the active ingredient; and (b) a suitable lubricant, the tablet, caplet or other compressed form of the pharmaceutical formulation generally becoming about 75% dissolved in phosphate buffer media within about 30 minutes. The present invention further provides a pharmaceutical formulation for oral administration which is pharmaceutically acceptable, and which produces a therapeutic response, in tablet, caplet or other compressed form which comprises: (a) potassium, sodium or Tris salt of oxaprozin as the active ingredient: (b) a suitable lubricant; and (c) a suitable binder, the tablet, caplet or other compressed form of the pharmaceutical formulation generally becoming about 75% dissolved in phosphate buffer media within about 30 minutes. The present invention still further provides a method for eliminating or ameliorating pain in an animal, and methods for treating inflammation and inflammation-associated disorders such as rheumatoid arthritis and osteoarthritis, and related disorders and conditions, in an animal, comprising administering a pharmaceutical formulation of the present invention, as described herein, to the animal. The pharmaceutical formulations of the present invention may only contain minor quantities of metallic stearates (less than 0.976% of the total percentage weight of a tablet or other compressed form containing such a formulation), such as the lubricants, magnesium, calcium and zinc stearate, in order to prevent any deleterious effect upon the disintegration and/or dissolution of tablets, caplets or other pressed forms of these formulations. Preferably, the pharmaceutical formulations of the present invention do not contain any metallic stearates. The pharmaceutical formulations of the present invention may also only contain minor quantities of the binder methylcellulose (less than 2% of the total percentage weight of a tablet containing such a formulation) in order to prevent any deleterious effect upon the disintegration and/or dissolution of tablets, caplets or other pressed forms of these formulations. Preferably, the pharmaceutical formulations of the present invention do not contain any methylcellulose.
In one 3-month study in monkeys using every-3-day dosing, tremors were observed, beginning 35 to 43 days after the beginning of dosing at and above 30 mg/kg (9 times the clinical exposure based on AUC comparison). Increased cellularity/hyperplasia of Schwann cells and nerve fiber degeneration (affecting axons and/or myelin) were observed at 30 mg/kg (9 times the clinical exposure based on AUC comparison) and above. Tremors and demyelination persisted in the fourth week of a 4-week reversibility period. A subsequent 26-week monkey study using weekly rezafungin dosing up to 30 mg/kg (6 times the clinical exposure based on AUC comparison) showed a non-dose dependent increase in tremors, axonal degeneration, or demyelination compared to controls beginning at doses similar to human exposures (5 mg/kg). In one animal in the 15 mg/kg cohort (3 times the clinical exposure based on AUC comparison), tremors persisted to the end of the 52-week reversibility period. In rats dosed weekly for 26 weeks, intravenous rezafungin was associated with an increased incidence of axonal/nerve fiber degeneration at 25 and 45 mg/kg (2- and 4-times the clinical dose based on AUC comparison) at the end of the 26-week reversibility period.

Rezafungin induced an acute transient histamine-release response in rats. In monkeys, both the vehicle and rezafungin induced a mild transient histamine-like response in some studies.
PURPOSE: To obtain a dermal preparation for external use excellent in keratin moisture retention and anti-itching effect comprising urea and amine soap of a higher fatty acid. CONSTITUTION: This dermal preparation comprises, as active ingredients 1-40%.wt. of urea and 0.1-10%.wt. of higher fatty acid amine soap. In addition, the preparation contains a higher alcohol, a water-soluble polymer, a water-soluble thickener and an oily component appropriately and adjusted to pH6-9 by adding a higher fatty acid and a buffer. Urea can be stabilized in the formulation by adding the higher fatty acid amine soap to the preparation. The use of an antihistaminica as an amine component in higher fatty acid amine soap, enables the coexistence of urea which is difficult to coexist with antihistamine.
Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
This invention relates to compositions comprising cellulose particles and methods for making and using same. This invention also relates to compositions comprising a fluid and particles comprising cellulose. Thus, disclosed herein are methods of manufacture, isolation, purification, and handling of cellulose particles. Also disclosed are uses for cellulose particles as additives in leavened or leavenable food products, or in an emulsion or emulsifiable product, or as a suspension aid, or in a thickened composition, or in a meat or meat analog product, or in a personal care formulation, or in a beauty formulation, or in a cosmetic formulation, or in a skin care formulation. Also disclosed are uses for cellulose particles in subterranean treatment compositions. Also disclosed are uses for cellulose particles in metal working compositions, cutting compositions, and stamping compositions. Also disclosed herein are resuspendable particles comprising cellulose. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Mindfulness-based smartphone apps have surged in popularity in recent years. Headspace - among the most popular of these platforms - has over 42 million users. Recent surveys indicate that 11% of U.S. adolescents have used mindfulness apps as a means of coping with anxiety or depressive symptoms, which increase substantially during the adolescent years. A growing body of research implicates rumination as being a transdiagnostic risk factor involved in the development of depression and anxiety in youth. Critically, mindfulness meditation has shown significant promise in targeting rumination, and ultimately improving depressive and anxiety symptoms. Mindfulness apps offer a convenient and cost-effective means for accessing mindfulness training, while being interactive and engaging for youth. Despite their growing popularity among teens, strikingly little research has been conducted on these apps. Two critical questions have yet to be addressed, which are strongly aligned with the NCCIH Strategic Plan: (1) what are the underlying neural and cognitive mechanisms that account for the beneficial effects of these apps and (2) for whom is app-based mindfulness well-suited. To address these gaps, adolescents (ages 13-18) will be randomly assigned to an app-delivered mindfulness course vs. an active control condition and will complete pre- and post-intervention resting state functional magnetic resonance imaging (fMRI) scans to probe static and dynamic functional connectivity within - and between - brain networks implicated in mindfulness training and rumination. In addition, cognitive tasks will be administered at pre- and post-intervention to assess attentional control abilities putatively enhanced by mindfulness training. Finally, mindfulness skills and changes in rumination will be assessed via smartphone-based ecological momentary assessment (EMA). First, the investigators will test whether changes in (1) brain functional connectivity (dynamic resting state functional connectivity via coactivation pattern analysis), (2) attentional control (Correct NoGo % on the SART task) and (3) acquisition and use of mindfulness skills (assessed via EMA) mediate between-group (i.e., app vs. control) differences in the reduction of rumination. Second, the investigators will test whether a machine learning model incorporating baseline clinical, demographic, and psychosocial characteristics can be used to identify which adolescents are predicted to benefit from app-based mindfulness training. Ultimately, such an algorithm may inform individual risk-benefit assessments that could be used to objectively communicate the probability of experiencing positive vs. adverse outcomes to users prior to engaging with a mindfulness app. Collectively, results are expected to advance (1) our understanding of the underlying mechanisms that account for the beneficial effects of app-based mindfulness training and (2) our ability to predict which adolescents are well-suited to these increasingly popular apps.
Speech disorders are significant barriers to the balanced development of a child. Many children in Poland are affected by lisps (sigmatism)-the incorrect articulation of sibilants. Since speech therapy diagnostics is complex and multifaceted, developing computer-assisted methods is crucial. This paper presents the results of assessing the usefulness of hybrid feature vectors extracted based on multimodal (video and audio) data for the place of articulation assessment in sibilants /s/ and /ʂ/. We used acoustic features and, new in this field, visual parameters describing selected articulators' texture and shape. Analysis using statistical tests indicated the differences between various sibilant realizations in the context of the articulation pattern assessment using hybrid feature vectors. In sound /s/, 35 variables differentiated dental and interdental pronunciation, and 24 were visual (textural and shape). For sibilant /ʂ/, we found 49 statistically significant variables whose distributions differed between speaker groups (alveolar, dental, and postalveolar articulation), and the dominant feature type was noise-band acoustic. Our study suggests hybridizing the acoustic description with video processing provides richer diagnostic information.